secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vericel Corp (VCEL)
CIK:        0000887359
Form:       8-K
Filed at:   2023-08-02T23:59:59+00:00
Accession:  0001628280-23-026579
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vericel Q2 revenue $45.9M (+24% YoY); raises FY2023 guidance to $190-197M
-------------------------------------------------------------------------

- Total net revenue $45.9M (+24% YoY); MACI $36.3M (+27%), Epicel $9.6M (+17%).
- Net loss $5.0M ($0.11 EPS) improved from $9.0M loss in Q2 2022; adjusted EBITDA $4.4M.
- Full-year 2023 revenue guidance raised to $190-197M from prior $184-192M; gross margin guidance high-60% maintained.
- MACI arthroscopic delivery program on track for 2024 commercial launch; human factors study planned Q3.
- Extended exclusive supply agreement with Matricel GmbH for MACI collagen membrane.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/887359/000162828023026579/0001628280-23-026579-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/887359/000162828023026579/vcel-20230802.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-026579

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer